- Home
- ESAB vs TGTX Comparison
ESAB vs TGTX Comparison
Compare ESAB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- TGTX
- Stock Information
- Founded
- ESAB 1904
- TGTX 1993
- Country
- ESAB United States
- TGTX United States
- Employees
- ESAB N/A
- TGTX N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- TGTX Health Care
- Exchange
- ESAB Nasdaq
- TGTX Nasdaq
- Market Cap
- ESAB 6.4B
- TGTX 5.5B
- IPO Year
- ESAB N/A
- TGTX 1995
- Fundamental
- Price
- ESAB $111.00
- TGTX $32.86
- Analyst Decision
- ESAB Strong Buy
- TGTX Strong Buy
- Analyst Count
- ESAB 8
- TGTX 4
- Target Price
- ESAB $143.38
- TGTX $54.75
- AVG Volume (30 Days)
- ESAB 514.1K
- TGTX 2.3M
- Earning Date
- ESAB 10-29-2025
- TGTX 11-03-2025
- Dividend Yield
- ESAB 0.36%
- TGTX N/A
- EPS Growth
- ESAB N/A
- TGTX N/A
- EPS
- ESAB 3.95
- TGTX 2.78
- Revenue
- ESAB $2,792,325,000.00
- TGTX $531,898,000.00
- Revenue This Year
- ESAB $3.25
- TGTX $82.31
- Revenue Next Year
- ESAB $8.37
- TGTX $49.05
- P/E Ratio
- ESAB $28.18
- TGTX $11.88
- Revenue Growth
- ESAB 1.19
- TGTX 100.88
- 52 Week Low
- ESAB $100.17
- TGTX $25.28
- 52 Week High
- ESAB $135.84
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- ESAB 47.44
- TGTX 53.68
- Support Level
- ESAB $103.49
- TGTX $30.15
- Resistance Level
- ESAB $116.08
- TGTX $31.45
- Average True Range (ATR)
- ESAB 3.08
- TGTX 1.24
- MACD
- ESAB -0.33
- TGTX 0.12
- Stochastic Oscillator
- ESAB 57.31
- TGTX 71.41
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.